LUN and HLUNB.CO Related Headlines
Go Back- FDA grants Lundbeck Fast Track status for narcolepsy drug candidate
- Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
- Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
- Lundbeck presents Phase 1b data for Parkinson's drug at conference
- Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026
LUN and HLUNB.CO Related Press Releases
Go Back- Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
- Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
- Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026
